Evaluation of the efficacy and safety of rosuvastatin combined with fasudil in patients with chronic obstructive pulmonary disease complicated with pulmonary hypertension
Evaluation of the efficacy and safety of rosuvastatin combined with fasudil in patients with chronic obstructive pulmonary disease complicated with pulmonary hypertension
Objective To explore the efficacy and safety of rosuvastatin combined with fasudil in patients with chronic obstructive pulmonary disease(COPD)complicated with pulmonary hypertension.Methods A total of 80 patients with COPD complicated with pulmonary hypertension admitted to Binzhou Central Hospital from February 2020 to March 2022 were divided into two groups according to the random number table method,with 40 cases in each group.The control group was treated with rosuvastatin,and the observation group was treated with fasudil on the basis of rosuvastatin.The clinical efficacy were compared,including lung function,pulmonary circulation indicators,and ventricular remodeling indicators before and after treatment,and adverse reactions were observed between the two groups.Results The total clinical effective rate of the observation group was significantly higher than that of the control group,with statistically significant difference(P<0.05).After treatment,the observation group had higher first second forced expiratory volume(FEV1),FEV1/forced vital capacity(FVC),tricuspid valve maximum reflux velocity(TRVmax),right ventricular ejection fraction(RVEF),right ventricular infarction(RVMI),and mean pulmonary arterial pressure(MPAP),aortic diameter(AO),and right ventricular end-diastolic basal transverse diameter(RVDD)compared to the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in adverse reactions between the two groups during treatment(P>0.05).Conclusion The combination of rosuvastatin and fasudil has a prominent clinical effect on COPD patients complicated with pulmonary hypertension,effectively improving lung function and pulmonary circulation indicators,as well as improving ventricular remodeling indicators.There are no significant adverse reactions during the treatment period,with high safety.
维普
万方数据